鹿瓜多肽促进膝骨性关节炎软骨细胞增殖机制的实验研究与临床观察
|
摘要
目的：探讨鹿瓜多肽促进膝骨性关节炎软骨细胞增殖的机制。
方法：实验研究：将50只新西兰大白兔随机分成模型组35只、假模组8只、正常组7只。模型组参照Hulth造模法造骨性关节炎动物模型,假模组仅作左膝关节内侧皮肤切开后缝合,正常组不做任何手术处理。4周后各组随机抽取2只兔子光镜下观察其关节软骨形态变化以及采用ELISA法检测其关节液内细胞因子IL-1β、TNF-α的水平。造模成功后将模型组随机平均分成治疗组、对照组、空白组。治疗组予鹿瓜多肽注射液0.5ml每日1次关节腔注射；对照组予维骨力每天两粒灌胃；空白组予生理盐水0.5ml每日1次关节腔注射。分别于注射后第1、15、30天抽取三组的关节液并获取其关节软骨组织。采用双抗体夹心ELISA法检测其关节液内细胞因子IL-1β、TNF-α的含量和TGF-β1的水平；采用HE染色观察其关节软骨的组织学变化、透射电镜观察其关节软骨细胞内结构变化；采用免疫组织化学法检测关节软骨细胞PCNA的表达,观察鹿瓜多肽促进关节软骨细胞增殖作用的情况。临床观察：将归类好后的50例早中期膝骨性关节炎患者平均随机分成治疗组、对照组。治疗组每日行鹿瓜多肽12ml加入0.9%氯化钠注射液250ml中静脉滴注,共一个疗程(15天)。对照组口服维骨力每次两粒(tid),连续30天。分别于干预后第1、15、30天抽取两组患者的关节液并采用双抗体夹心ELISA法检测其关节液内细胞因子IL-1β、TNF-α的含量和TGF-β1的水平,观察鹿瓜多肽对以上细胞因子的调节作用,进而分析鹿瓜多肽注射液对KOA患者软骨细胞增殖的情况。
结果：实验研究：造模4周后,光镜下观察模型组关节软骨形态明显改变,造模成功后对照组与空白组的IL-1β、TNF-α含量在第15、30天不同时期均高于治疗组,两组间比较有较明显的差异(P<0.01)；其TGF-β1水平在第15、30天不同时期均低于治疗组,两组间比较有较明显的差异(P<0.01)；治疗组的软骨细胞增殖指数与对照组、空白组的软骨细胞增殖指数的比较有显著性差(P<0.01)。HE染色：空白组在第30天时能见大部分软骨陷窝内细胞消失,边缘破坏且粗糙不平严重,同时软骨细胞增生现象明显；对照组在第30天时能见部分软骨陷窝内细胞消失,边缘存在破坏且粗糙不平情况,同时也有少量软骨细胞增生现象；治疗组在第30天时软骨结构清晰可辨,软骨细胞排列整齐,潮线完整,没有出现增生现象。透射电镜：空白组在第30天时其胞质萎缩,染色质不均匀明显,细胞可见凋亡小体形成；对照组在第30天时其染色质存在少量不均匀现象,部分细胞可见凋亡小体形成；治疗组在第30天时则可见其软骨细胞表面微绒毛较多,胞膜、胞核较为完整,胞质内有较多的粗面内质网、线粒体等,染色质分布呈较均匀现象。临床观察：治疗组的细胞因子IL-1β、TNF-α含量在药物干预后第15、30天不同时期均低于对照组,两组比较有明显的差异(P<0.01)；其TGF-β1水平在第15、30天不同时期均高于对照组,两组比较有明显的差异(P<0.01)。治疗组的临床症状较对照组的临床症状有明显的好转。
结论：鹿瓜多肽可能是通过诱导减少关节液内细胞因子IL-1β、TNF-α的含量及上调转化生长因子TGF-p1的水平这一作用机制来促进膝骨性关节炎软骨细胞增殖的。
Objective:The Mechanism of Study On Cervus and Cucumis Polypeptide Injection on Promoting Chondrocytes Proliferation with Knee Osteoarthritis。
Methods:The Experimental study:The 50 New Zealand white rabbits were randomly divided into model group of 35. sham module 8, the normal group of 7。Hulth model modeling method group made reference to osteoarthritis animal models, fake modules for the left only after the skin incision medial suture, normal group without any surgical treatment。After 4 weeks in each group randomly selected from two rabbits were observed under light microscope and morphological changes of articular cartilage detected by ELISA in synovial fluid cytokine IL-1β、TNF-αlevels。Successful model after the model group were randomly divided into treatment group and control group and blank group。Treated group Injection 0.5ml Lugua polypeptide articular injection of evey day; The control group for every two-dimensional Glucosamine orally; 0.5ml normal saline blank group articular injection of 1 day。Were taken after injection one day、15 and 30 days and synovial fluid of three groups for the articular cartilage。Double antibody sandwich ELISA assay in synovial fluid cytokine IL-1β、TNF-αlevels and the level of TGF-β1。Observed by HE staining of histological changes of articular cartilage, transmission electron microscopy to observe the structural changes in articular cartilage cells; Detected by immunohistochemistry PCNA expression in articular chondrocytes was observed Lugua peptides promote cell proliferation of articular cartilage situation.。The Clinical observation:After the classification of 50 cases of early and mid knee osteoarthritis were randomly divided into treatment group、the control group on average。Line treatment group Lugua polypeptide 12ml daily in 0.9% sodium chloride injection in the intravenous infusion of 250ml of a course of treatment (15 days)。Glucosamine control group was treated every two-dimensional (tid), in all 30 days。Intervention were taken after 1day、15 and 30 days and synovial fluid of patients with two groups by double antibody sandwich ELISA assay in synovial fluid cytokine IL-1β、TNF-a levels and the level of TGF-β1o Peptides on the above observation Lugua regulation of cytokines, and then analyzes Lugua peptide injection on cartilage cell proliferation in patients with KOA situation。
Results:The Experimental study:After 4 weeks of modeling, light microscope morphological changes of articular cartilage in model group, after the success of the modeling group and blank control group. Their IL-1βand TNF-a levels in different periods of 15 and 30 days higher than the treatment group o Between the two groups have a more significant difference (P<0.01); The TGF-β1 levels at different periods of 15 and 30 days were lower than the treatment group, two groups have a more significant difference (P<0.01); the treatment group, the cartilage cell proliferation with the control group and blank group, the proliferation of cartilage cells The comparison of the significant difference (P<0.01)o HE staining:30 days control group visibility in most of the cartilage cell lacunae disappeared, and the rough edge of serious damage, and cartilage cell proliferation significantly; 30 days in the control group some visibility within the cells of cartilage lacunae disappeared, there is destruction and rough edges of the situation, but also a small amount of cartilage cell proliferation; The treatment group in 30 days, clearly visible cartilage, cartilage cells arranged in neat rows, tidal line complete, there was no proliferation。TEM:The blank group in 30 days of its cytoplasmic shrinkage, chromatin was heterogeneous, cell apoptotic body formation; The control group in 30 days, there is a small amount of its uneven chromatin. some cells were apoptotic body formation; Treatment group at 30 days may be reflected in its cell surface microvilli more cartilage in membrane, the nucleus is more complete, more cytoplasm of rough endoplasmic reticulum in mitochondria, chromatin showed a more uniform distribution of the phenomenon。The Clinical observation:the treatment group of cytokines IL-1β、TNF-a levels in 15 and 30 days after drug intervention in different periods were lower than the control group, there were significant differences between the two groups (P<0.01); the TGF-βl level of 15 and 30 days in different periods were higher, there were significant differences between the two groups (P<0.01)。The clinical symptoms of the treatment group better than in the control group, there is a marked improvement in clinical symptoms。
Conclusion:CCPI may be reduced by induction of cytokines in synovial fluid IL-1β、TNF-a levels and increased TGF-β1 level mechanisms to promote the role of knee osteoarthritis cartilage cell proliferation。
方法：实验研究：将50只新西兰大白兔随机分成模型组35只、假模组8只、正常组7只。模型组参照Hulth造模法造骨性关节炎动物模型,假模组仅作左膝关节内侧皮肤切开后缝合,正常组不做任何手术处理。4周后各组随机抽取2只兔子光镜下观察其关节软骨形态变化以及采用ELISA法检测其关节液内细胞因子IL-1β、TNF-α的水平。造模成功后将模型组随机平均分成治疗组、对照组、空白组。治疗组予鹿瓜多肽注射液0.5ml每日1次关节腔注射；对照组予维骨力每天两粒灌胃；空白组予生理盐水0.5ml每日1次关节腔注射。分别于注射后第1、15、30天抽取三组的关节液并获取其关节软骨组织。采用双抗体夹心ELISA法检测其关节液内细胞因子IL-1β、TNF-α的含量和TGF-β1的水平；采用HE染色观察其关节软骨的组织学变化、透射电镜观察其关节软骨细胞内结构变化；采用免疫组织化学法检测关节软骨细胞PCNA的表达,观察鹿瓜多肽促进关节软骨细胞增殖作用的情况。临床观察：将归类好后的50例早中期膝骨性关节炎患者平均随机分成治疗组、对照组。治疗组每日行鹿瓜多肽12ml加入0.9%氯化钠注射液250ml中静脉滴注,共一个疗程(15天)。对照组口服维骨力每次两粒(tid),连续30天。分别于干预后第1、15、30天抽取两组患者的关节液并采用双抗体夹心ELISA法检测其关节液内细胞因子IL-1β、TNF-α的含量和TGF-β1的水平,观察鹿瓜多肽对以上细胞因子的调节作用,进而分析鹿瓜多肽注射液对KOA患者软骨细胞增殖的情况。
结果：实验研究：造模4周后,光镜下观察模型组关节软骨形态明显改变,造模成功后对照组与空白组的IL-1β、TNF-α含量在第15、30天不同时期均高于治疗组,两组间比较有较明显的差异(P<0.01)；其TGF-β1水平在第15、30天不同时期均低于治疗组,两组间比较有较明显的差异(P<0.01)；治疗组的软骨细胞增殖指数与对照组、空白组的软骨细胞增殖指数的比较有显著性差(P<0.01)。HE染色：空白组在第30天时能见大部分软骨陷窝内细胞消失,边缘破坏且粗糙不平严重,同时软骨细胞增生现象明显；对照组在第30天时能见部分软骨陷窝内细胞消失,边缘存在破坏且粗糙不平情况,同时也有少量软骨细胞增生现象；治疗组在第30天时软骨结构清晰可辨,软骨细胞排列整齐,潮线完整,没有出现增生现象。透射电镜：空白组在第30天时其胞质萎缩,染色质不均匀明显,细胞可见凋亡小体形成；对照组在第30天时其染色质存在少量不均匀现象,部分细胞可见凋亡小体形成；治疗组在第30天时则可见其软骨细胞表面微绒毛较多,胞膜、胞核较为完整,胞质内有较多的粗面内质网、线粒体等,染色质分布呈较均匀现象。临床观察：治疗组的细胞因子IL-1β、TNF-α含量在药物干预后第15、30天不同时期均低于对照组,两组比较有明显的差异(P<0.01)；其TGF-β1水平在第15、30天不同时期均高于对照组,两组比较有明显的差异(P<0.01)。治疗组的临床症状较对照组的临床症状有明显的好转。
结论：鹿瓜多肽可能是通过诱导减少关节液内细胞因子IL-1β、TNF-α的含量及上调转化生长因子TGF-p1的水平这一作用机制来促进膝骨性关节炎软骨细胞增殖的。
Objective:The Mechanism of Study On Cervus and Cucumis Polypeptide Injection on Promoting Chondrocytes Proliferation with Knee Osteoarthritis。
Methods:The Experimental study:The 50 New Zealand white rabbits were randomly divided into model group of 35. sham module 8, the normal group of 7。Hulth model modeling method group made reference to osteoarthritis animal models, fake modules for the left only after the skin incision medial suture, normal group without any surgical treatment。After 4 weeks in each group randomly selected from two rabbits were observed under light microscope and morphological changes of articular cartilage detected by ELISA in synovial fluid cytokine IL-1β、TNF-αlevels。Successful model after the model group were randomly divided into treatment group and control group and blank group。Treated group Injection 0.5ml Lugua polypeptide articular injection of evey day; The control group for every two-dimensional Glucosamine orally; 0.5ml normal saline blank group articular injection of 1 day。Were taken after injection one day、15 and 30 days and synovial fluid of three groups for the articular cartilage。Double antibody sandwich ELISA assay in synovial fluid cytokine IL-1β、TNF-αlevels and the level of TGF-β1。Observed by HE staining of histological changes of articular cartilage, transmission electron microscopy to observe the structural changes in articular cartilage cells; Detected by immunohistochemistry PCNA expression in articular chondrocytes was observed Lugua peptides promote cell proliferation of articular cartilage situation.。The Clinical observation:After the classification of 50 cases of early and mid knee osteoarthritis were randomly divided into treatment group、the control group on average。Line treatment group Lugua polypeptide 12ml daily in 0.9% sodium chloride injection in the intravenous infusion of 250ml of a course of treatment (15 days)。Glucosamine control group was treated every two-dimensional (tid), in all 30 days。Intervention were taken after 1day、15 and 30 days and synovial fluid of patients with two groups by double antibody sandwich ELISA assay in synovial fluid cytokine IL-1β、TNF-a levels and the level of TGF-β1o Peptides on the above observation Lugua regulation of cytokines, and then analyzes Lugua peptide injection on cartilage cell proliferation in patients with KOA situation。
Results:The Experimental study:After 4 weeks of modeling, light microscope morphological changes of articular cartilage in model group, after the success of the modeling group and blank control group. Their IL-1βand TNF-a levels in different periods of 15 and 30 days higher than the treatment group o Between the two groups have a more significant difference (P<0.01); The TGF-β1 levels at different periods of 15 and 30 days were lower than the treatment group, two groups have a more significant difference (P<0.01); the treatment group, the cartilage cell proliferation with the control group and blank group, the proliferation of cartilage cells The comparison of the significant difference (P<0.01)o HE staining:30 days control group visibility in most of the cartilage cell lacunae disappeared, and the rough edge of serious damage, and cartilage cell proliferation significantly; 30 days in the control group some visibility within the cells of cartilage lacunae disappeared, there is destruction and rough edges of the situation, but also a small amount of cartilage cell proliferation; The treatment group in 30 days, clearly visible cartilage, cartilage cells arranged in neat rows, tidal line complete, there was no proliferation。TEM:The blank group in 30 days of its cytoplasmic shrinkage, chromatin was heterogeneous, cell apoptotic body formation; The control group in 30 days, there is a small amount of its uneven chromatin. some cells were apoptotic body formation; Treatment group at 30 days may be reflected in its cell surface microvilli more cartilage in membrane, the nucleus is more complete, more cytoplasm of rough endoplasmic reticulum in mitochondria, chromatin showed a more uniform distribution of the phenomenon。The Clinical observation:the treatment group of cytokines IL-1β、TNF-a levels in 15 and 30 days after drug intervention in different periods were lower than the control group, there were significant differences between the two groups (P<0.01); the TGF-βl level of 15 and 30 days in different periods were higher, there were significant differences between the two groups (P<0.01)。The clinical symptoms of the treatment group better than in the control group, there is a marked improvement in clinical symptoms。
Conclusion:CCPI may be reduced by induction of cytokines in synovial fluid IL-1β、TNF-a levels and increased TGF-β1 level mechanisms to promote the role of knee osteoarthritis cartilage cell proliferation。
引文
[1]江陟郝,修忠标.中药防治膝骨性关节炎关节软骨退变的作用机制研究进展[J].九江医学,2009,6,24(2)：98.
[2]高仰贤,江蓉星.骨性关节炎发病机制的国内研究进展[J].中医正骨,2005,4(17)：55.
[3]傅欣,林霖,张继英,等.骨性关节炎兔关节软骨关节液细胞因子IL-1β和TNF-a变化的研究[J].中国运动医学杂志,2007,26(6)：706-723。
[4]沈海丽,杜兰生,魏佳熙,等.联合鹿瓜多肽注射液治疗骨性关节炎的疗效分析[J].中国医药,2006,1,10：632-633.
[5]刘献祥,李西海,周江涛.改良Hulth造模法复制膝骨性关节炎的实验研[J]中国中西医结合杂志,2005,25(12)：1104-1108.
[6]舒谦,曹亚飞,卿茂盛.六味地黄汤对实验性骨关节炎兔软骨细胞凋亡与增殖的体内实验[J].中医药学刊,2006,7,24：1260-1262.
[7]Lawrence RC,Felson DT,Helmick CG et.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States,Part IL.Arthritis Rheum,2008,58(1):20-55.
[8]Qin XY,Li XX,Berghea F,Suteanu S.Comparative study on Chinese medicine andwestern medicine for treatment of osteoarthritis of the knee in Caucasian patients.Zhong guo Zhen Jiu,2008,28(6):450-486.
[9]刘献祥,李西海,周江涛,等.透骨消痛颗粒防治膝骨性关节炎的机理研究[J].中国中西医结合杂志,2007,27(1)：48-56.
[10]Yoon HS,Kim HA,Song YW.Inhibition of NF-kappaB renders human juvenile costal chondrocyte cell lines sensitive to TNF-alpha-mediated cell death.Rheumatol Int,2006,26(3):201-208.
[13]方洪松,明僵化,等.鹿瓜多肽注射液治疗膝关节骨关节炎的临床观察[J].中国骨与关节损伤杂志,2007,2,22：169.
[12]周海蓉,肖振良.健骨胶囊对兔骨性关节炎软骨及滑膜影响的实验研究[J].中国中医药科技,2008,15(5)：333-346.
[13]方洪松,明僵化,等.鹿瓜多肽注射液治疗膝关节骨关节炎的临床观察[J].中国骨与关节损伤杂志,2007,2,22：168.
[14]韩其蔚,方彬,梅俊华.维骨力治疗骨关节炎的临床疗效[J].中国老年学杂志,2004,05,24：450
[15]宁显明,樊奥光,徐传毅,等.补肾中药对膝骨关节炎软骨TGF-β1表达的影响[J].中国中医骨伤科杂志,2004,12(1)：35-38.
[16]Cortial D,Gouttenoire J,Rousseau CF.Activation by IL-1 of bovine articular chondrocytes in culture within a 3D collagen-based scaffold.An in vitro model to address the effect of compounds with therapeutic potential in osteoarthritis. Osteoarthritis and Cartilage,2006,14(7):626-660.
[17]杨瑞甫,胡蕴玉,吴银松,等.兔骨关节炎两种动物模型的比较[J].中国矫形外科杂志2006,19(14)：1497-1499.
[18]郭礼跃,胡慧华,米健国.古方稀莶丸对膝骨性关节炎模型家兔关节液中IL-lb. TNFa含量及关节软骨细胞形态学的影响[J].中国骨伤,2006,19(6)：377-378.
[19]CappelloF,RibbeneA,CampanellaC,CzameckaAM,etal.Thevalueofimmunohistochemical research on PCNA,p53 and heat shock proteins in prostate cancer managementa review.Eur J Histochem,2006,50(1): 25-34.
[20]Y.Xiang,K.Masuko-Hongo,T.Sekine,et al.Expression of proteinase activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1β,TNF-aand TGF. OsteoArthritis and Cartilage,2006,14 (11): 1163-1173.
[21]王和鸣,余丹丹,汤亭亭,等.龟鹿二仙胶汤及其拆方对关节软骨细胞增殖的作用[J].中国中医骨伤科杂志,2007,15(7)：40-49.
[22]Sengupta K,Alluri KV,Satish AR.A double blind,randomized,placebo controlled study of the efficacy and safety of 5-Loxin(R)for treatment of osteoarthritis of theknee.Arthritis Res Ther,2008;10(4):R85.
[23]Hajjar D,Santos MF,Kimura ET.Propulsive appliance stimulates the synthesis of insulin-like growth factors I and II in the mandibular condylar cartilage of young rats.Arch oral Biol,2003,48:635-642.
[24]Dai SM,Shan ZZ,Nishioka K,et al.Implication of interleukin-18 inproduction of matrix metalloproteinases in articular chondrocytes in arthritis:direcaeffect on chondrocytesmay not be pivotal[J]. Ann Rheum Dis,2005,64(5):735-742.
[25]郭礼跃,胡慧华,等.古方稀莶丸对膝骨性关节炎模型家兔关节液IL-lb与TNF-a含量及关节软骨细胞形态学的影响[J].中国骨伤,2006,19(6)：377.
[26]周斌,樊粤光,曾意荣.中药关节康治疗膝骨性关节炎的临床研究[J].广州中医药大学学报,2006,23(6)：476-480.
[27]郭礼跃,胡慧华,米健国.古方稀莶丸对膝骨性关节炎模型家兔关节液中IL-lb、 TNFa含量及关节软骨细胞形态学的影响[J].中国骨伤,2006,19(6)：378.
[28]马进峰,陈晓亮,王英振,等.软骨生长因子对兔软骨细胞作用的实验研究.中华外科杂志,2002,40(8)：601-606.
[29]Hu DN, Yang PY, Ku MC,et al.Isolation and cultivation of human articular chondrocytes. Kaohsiung JMed Sci,2002,18(3):112-124.
[30]吴洪,徐华洲,韦哲.十一方酒对兔膝骨性关节炎TGF-β1以及病理形态学的影响[J].中国医药导报,2007,4(20)：134-135.
[31]Esmeralda N Blaney Davidson,Elly L Vitters,et al.TGFβ-induced cartilage repair ismaintained but fibrosis is blocked in the presence of Smad7.Arthritis Res Ther.2006 Mar 29;8(3):R65.
[32]林建华,邓凌霄,吴朝阳.鹿茸多肽促进软骨细胞增殖机制的初步探讨[J].中华创伤骨科杂志2007,12,9(12)：1161-1163.
[33]林建华,吴朝阳.鹿茸多肽对兔骨髓间质干细胞体外增殖的影响[J].中华实验外科杂志2005,7,22(7)：827-830.
[34]鞠大宏,贾红伟,吴皓,等.鹿瓜多肽注射液对CⅡ诱导的免疫性关节炎大鼠血清TNF-α、IL-1β以及CⅡ抗体活性的影响[J].中国中医基础医学杂志,2003,09,11：17-21.
[35]陈秀玲.穴位注射鹿瓜多肽注射液治疗膝骨关节炎的临床研究[J].上海针灸杂志,2009,28,1：44-45.
[36]黄俊卿.中西医结合治疗膝关节骨性关节炎60例观察[J].中医研究,2009,33,4：20-22.
[37]吴文锋,陈秀玲.穴位注射治疗老年性膝骨性关节炎60例临床疗效分析[J].贵阳中医学院学报,2007,29,01：38-39.
[38]林建华,邓凌霄,吴朝阳.鹿茸多肽促进软骨细胞增殖机制的初步探讨[J].中华创伤骨科杂志2007,12,9(12)：1161-1162.
[39]林建华,吴朝阳.鹿茸多肽对兔骨髓间质干细胞体外增殖的影响[J].中华实验外科杂志2005,7,22(7)：828.
[40]鞠大宏,贾红伟,吴皓,等鹿瓜多肽注射液对CⅡ诱导的免疫性关节炎大鼠血清TNF-α IL-1β以及CⅡ抗体活性的影响[J].中国中医基础医学杂志,2003,09,11：17-21.
[41]段永宏,李敬娥,厉孟.鹿瓜多肽对去卵巢大鼠骨密度及松质骨中TGF-β1表达的影响[J].西北国防医学杂志,2008,29,1：28-30.
[42]周海蓉,肖振良.健骨胶囊对兔骨性关节炎软骨及滑膜影响的实验研究[J].中国中医药科技,2008,15(5)：333-346.
[43]Y.Xiang,K.Masuko-Hongo,T.Sekine,et al.Expression of proteinase activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1β，TNF-aand TGF.OsteoArthritis and Cartilage,2006,14 (11): 1163-1173.
[44]Y.Xiang,K.Masuko-Hongo,T.Sekine,et al,Expression of proteinase activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1β,TNF-aand TGF.OsteoArthritis and Cartilage,2006,14 (11): 1163-1173.
[45]姬磊.鹿瓜多肽关节腔注射治疗膝骨关节炎的观察[J].医药论坛杂志2008.29,17：72-74。
[46]吴文锋,陈秀玲.穴位注射治疗老年性膝骨性关节炎60例临床疗效分析[J].贵阳中医学院学报,2007,29,01：38-39.
[47]陈秀玲.穴位注射鹿瓜多肽注射液治疗膝骨关节炎的临床研究[J].上海针灸杂志,2009,28,1：44-45
[48]方洪松,明僵化,等.鹿瓜多肽注射液治疗膝关节骨关节炎的临床观察[J].中国骨与关节损伤杂志2007,2,22：168.
[49]魏志学.鹿瓜多肽治疗骨性关节炎52例疗效观察[J].昆明医学院学报,2007,28,2B：245-246.
[50]沈海丽,杜兰生,魏佳熙,等.联合鹿瓜多肽注射液治疗骨性关节炎的疗效分析[J].中国医药,2006,1,10：632-633.
[1]何伟,张俐,王维佳,宫恩年.骨病临床研究,北京[M].北京科学技术出版社.2006,1(1)：133-144.
[2]何斌,史晨辉.尿激酶型纤溶酶原激活物系统与软骨降解[J].农垦医学2005,6,27(3)：229-231.
[3]江蓉星,熊华,金桂花.骨性关节炎的临床治疗研究概况[J].中国中医骨伤科杂志2003,2,11(1)：57-59.
[4]曲俊才.膝骨关节炎模型兔关节液中细胞因子白细胞介素1水平及复方归芪液的干预效应[J].中国组织工程研究与临床康复2008,12：20-22.
[5]李西海,梁文娜.软骨下骨骨重塑与骨关节炎的关系[J].国际骨科学杂志2007,1-28(1)：35-37.
[6]刘献祥,等.透骨消痛颗粒防治膝骨性关节炎的机理研究[J].中国中西结合杂志2007,1-27(1)：50-53.
[7]何帮剑,等.玻璃酸钠注射结合中药熏洗治疗膝关节骨性关节炎疗效观察[J].辽宁中医药大学学报2008,10(8)：97-98.
[8]鞠传宝,初海滨,殷泽刚.补肾活血中药治疗膝骨性关节炎的研究进展[J].中医正骨2008,8,20(8)：70-73.
[9]乐宇民,杜建.补肾活血法在治疗骨关节炎中的应用[J].福建中医学院学报2004,2,14(1)：43-45.
[10]王秀华,苏姿兵,田万斌.丹参注射液对兔骨关节炎软骨的影响[J].辽宁中医杂志2003,10,30(10)：860-861
[11]段戡,周江南,成平.丹参加玻璃酸钠关节内注射对家兔实验性膝骨性关节炎软骨退变的影响[J].中医正骨2007,2,19(2)：4-6.
[12]张梅.马钱子对骨关节炎中软骨细胞凋亡与增殖的影响[J].北京中医药大学学报2003,8(5)：35-38.
[13]兰靖杰,戴七一.推拿手法治疗膝关节骨性关节炎研究进展[J].广西中医学院学报2006,9(4)：73-75.
[14]邵华磊,邵尔浩,王继东.手法加中药透敷治疗膝关节骨性关节炎[J].河南中医2005,25,4：49-501.
[15]胡兆平,余有志,岳国平.自助手法配合中药熏洗治疗膝关节骨性关节炎[J].现代中西医结合杂志2006,15(9)：1138.
[16]王珍,李矗.中药复方治疗骨性关节炎的实验研究进展[J].中南药学2007,12,5,(6)：539-541.
[17]牛维,等.补肾活血中药促进体外培养软骨细胞增殖和蛋白质合成的作用[J].中国临床康复2006,10(19)：50-52.
[18]邵敏.补肾活血中药对体外培养软骨细胞SOD, NOS的影响[J].福建中医药2006,37(4)：48-49.
[19]刘坤,刘盛华,宋贵杰.中药防治膝关节炎实验研究概况第11届全国中西医结合骨伤科学术研讨会论文汇编[C]2003：173-174.
[20]陈桂林,王嵩峰.中药内服治疗膝骨性关节炎的实验研究进展[J].甘肃中医2006,19(8)：48-50.
[21]陈崇伟,卫小春.关节软骨胶原变化与骨关节炎的关系[J].中华风湿病学杂志2003,1,7(1)：43-45.
[22]李赛波,吴耀持.膝骨性关节炎组织形态及细胞因子变化与中医药干预的影响[J].中国组织工程与临床康复2008,12(7)：1313-1317.
[2]高仰贤,江蓉星.骨性关节炎发病机制的国内研究进展[J].中医正骨,2005,4(17)：55.
[3]傅欣,林霖,张继英,等.骨性关节炎兔关节软骨关节液细胞因子IL-1β和TNF-a变化的研究[J].中国运动医学杂志,2007,26(6)：706-723。
[4]沈海丽,杜兰生,魏佳熙,等.联合鹿瓜多肽注射液治疗骨性关节炎的疗效分析[J].中国医药,2006,1,10：632-633.
[5]刘献祥,李西海,周江涛.改良Hulth造模法复制膝骨性关节炎的实验研[J]中国中西医结合杂志,2005,25(12)：1104-1108.
[6]舒谦,曹亚飞,卿茂盛.六味地黄汤对实验性骨关节炎兔软骨细胞凋亡与增殖的体内实验[J].中医药学刊,2006,7,24：1260-1262.
[7]Lawrence RC,Felson DT,Helmick CG et.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States,Part IL.Arthritis Rheum,2008,58(1):20-55.
[8]Qin XY,Li XX,Berghea F,Suteanu S.Comparative study on Chinese medicine andwestern medicine for treatment of osteoarthritis of the knee in Caucasian patients.Zhong guo Zhen Jiu,2008,28(6):450-486.
[9]刘献祥,李西海,周江涛,等.透骨消痛颗粒防治膝骨性关节炎的机理研究[J].中国中西医结合杂志,2007,27(1)：48-56.
[10]Yoon HS,Kim HA,Song YW.Inhibition of NF-kappaB renders human juvenile costal chondrocyte cell lines sensitive to TNF-alpha-mediated cell death.Rheumatol Int,2006,26(3):201-208.
[13]方洪松,明僵化,等.鹿瓜多肽注射液治疗膝关节骨关节炎的临床观察[J].中国骨与关节损伤杂志,2007,2,22：169.
[12]周海蓉,肖振良.健骨胶囊对兔骨性关节炎软骨及滑膜影响的实验研究[J].中国中医药科技,2008,15(5)：333-346.
[13]方洪松,明僵化,等.鹿瓜多肽注射液治疗膝关节骨关节炎的临床观察[J].中国骨与关节损伤杂志,2007,2,22：168.
[14]韩其蔚,方彬,梅俊华.维骨力治疗骨关节炎的临床疗效[J].中国老年学杂志,2004,05,24：450
[15]宁显明,樊奥光,徐传毅,等.补肾中药对膝骨关节炎软骨TGF-β1表达的影响[J].中国中医骨伤科杂志,2004,12(1)：35-38.
[16]Cortial D,Gouttenoire J,Rousseau CF.Activation by IL-1 of bovine articular chondrocytes in culture within a 3D collagen-based scaffold.An in vitro model to address the effect of compounds with therapeutic potential in osteoarthritis. Osteoarthritis and Cartilage,2006,14(7):626-660.
[17]杨瑞甫,胡蕴玉,吴银松,等.兔骨关节炎两种动物模型的比较[J].中国矫形外科杂志2006,19(14)：1497-1499.
[18]郭礼跃,胡慧华,米健国.古方稀莶丸对膝骨性关节炎模型家兔关节液中IL-lb. TNFa含量及关节软骨细胞形态学的影响[J].中国骨伤,2006,19(6)：377-378.
[19]CappelloF,RibbeneA,CampanellaC,CzameckaAM,etal.Thevalueofimmunohistochemical research on PCNA,p53 and heat shock proteins in prostate cancer managementa review.Eur J Histochem,2006,50(1): 25-34.
[20]Y.Xiang,K.Masuko-Hongo,T.Sekine,et al.Expression of proteinase activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1β,TNF-aand TGF. OsteoArthritis and Cartilage,2006,14 (11): 1163-1173.
[21]王和鸣,余丹丹,汤亭亭,等.龟鹿二仙胶汤及其拆方对关节软骨细胞增殖的作用[J].中国中医骨伤科杂志,2007,15(7)：40-49.
[22]Sengupta K,Alluri KV,Satish AR.A double blind,randomized,placebo controlled study of the efficacy and safety of 5-Loxin(R)for treatment of osteoarthritis of theknee.Arthritis Res Ther,2008;10(4):R85.
[23]Hajjar D,Santos MF,Kimura ET.Propulsive appliance stimulates the synthesis of insulin-like growth factors I and II in the mandibular condylar cartilage of young rats.Arch oral Biol,2003,48:635-642.
[24]Dai SM,Shan ZZ,Nishioka K,et al.Implication of interleukin-18 inproduction of matrix metalloproteinases in articular chondrocytes in arthritis:direcaeffect on chondrocytesmay not be pivotal[J]. Ann Rheum Dis,2005,64(5):735-742.
[25]郭礼跃,胡慧华,等.古方稀莶丸对膝骨性关节炎模型家兔关节液IL-lb与TNF-a含量及关节软骨细胞形态学的影响[J].中国骨伤,2006,19(6)：377.
[26]周斌,樊粤光,曾意荣.中药关节康治疗膝骨性关节炎的临床研究[J].广州中医药大学学报,2006,23(6)：476-480.
[27]郭礼跃,胡慧华,米健国.古方稀莶丸对膝骨性关节炎模型家兔关节液中IL-lb、 TNFa含量及关节软骨细胞形态学的影响[J].中国骨伤,2006,19(6)：378.
[28]马进峰,陈晓亮,王英振,等.软骨生长因子对兔软骨细胞作用的实验研究.中华外科杂志,2002,40(8)：601-606.
[29]Hu DN, Yang PY, Ku MC,et al.Isolation and cultivation of human articular chondrocytes. Kaohsiung JMed Sci,2002,18(3):112-124.
[30]吴洪,徐华洲,韦哲.十一方酒对兔膝骨性关节炎TGF-β1以及病理形态学的影响[J].中国医药导报,2007,4(20)：134-135.
[31]Esmeralda N Blaney Davidson,Elly L Vitters,et al.TGFβ-induced cartilage repair ismaintained but fibrosis is blocked in the presence of Smad7.Arthritis Res Ther.2006 Mar 29;8(3):R65.
[32]林建华,邓凌霄,吴朝阳.鹿茸多肽促进软骨细胞增殖机制的初步探讨[J].中华创伤骨科杂志2007,12,9(12)：1161-1163.
[33]林建华,吴朝阳.鹿茸多肽对兔骨髓间质干细胞体外增殖的影响[J].中华实验外科杂志2005,7,22(7)：827-830.
[34]鞠大宏,贾红伟,吴皓,等.鹿瓜多肽注射液对CⅡ诱导的免疫性关节炎大鼠血清TNF-α、IL-1β以及CⅡ抗体活性的影响[J].中国中医基础医学杂志,2003,09,11：17-21.
[35]陈秀玲.穴位注射鹿瓜多肽注射液治疗膝骨关节炎的临床研究[J].上海针灸杂志,2009,28,1：44-45.
[36]黄俊卿.中西医结合治疗膝关节骨性关节炎60例观察[J].中医研究,2009,33,4：20-22.
[37]吴文锋,陈秀玲.穴位注射治疗老年性膝骨性关节炎60例临床疗效分析[J].贵阳中医学院学报,2007,29,01：38-39.
[38]林建华,邓凌霄,吴朝阳.鹿茸多肽促进软骨细胞增殖机制的初步探讨[J].中华创伤骨科杂志2007,12,9(12)：1161-1162.
[39]林建华,吴朝阳.鹿茸多肽对兔骨髓间质干细胞体外增殖的影响[J].中华实验外科杂志2005,7,22(7)：828.
[40]鞠大宏,贾红伟,吴皓,等鹿瓜多肽注射液对CⅡ诱导的免疫性关节炎大鼠血清TNF-α IL-1β以及CⅡ抗体活性的影响[J].中国中医基础医学杂志,2003,09,11：17-21.
[41]段永宏,李敬娥,厉孟.鹿瓜多肽对去卵巢大鼠骨密度及松质骨中TGF-β1表达的影响[J].西北国防医学杂志,2008,29,1：28-30.
[42]周海蓉,肖振良.健骨胶囊对兔骨性关节炎软骨及滑膜影响的实验研究[J].中国中医药科技,2008,15(5)：333-346.
[43]Y.Xiang,K.Masuko-Hongo,T.Sekine,et al.Expression of proteinase activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1β，TNF-aand TGF.OsteoArthritis and Cartilage,2006,14 (11): 1163-1173.
[44]Y.Xiang,K.Masuko-Hongo,T.Sekine,et al,Expression of proteinase activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1β,TNF-aand TGF.OsteoArthritis and Cartilage,2006,14 (11): 1163-1173.
[45]姬磊.鹿瓜多肽关节腔注射治疗膝骨关节炎的观察[J].医药论坛杂志2008.29,17：72-74。
[46]吴文锋,陈秀玲.穴位注射治疗老年性膝骨性关节炎60例临床疗效分析[J].贵阳中医学院学报,2007,29,01：38-39.
[47]陈秀玲.穴位注射鹿瓜多肽注射液治疗膝骨关节炎的临床研究[J].上海针灸杂志,2009,28,1：44-45
[48]方洪松,明僵化,等.鹿瓜多肽注射液治疗膝关节骨关节炎的临床观察[J].中国骨与关节损伤杂志2007,2,22：168.
[49]魏志学.鹿瓜多肽治疗骨性关节炎52例疗效观察[J].昆明医学院学报,2007,28,2B：245-246.
[50]沈海丽,杜兰生,魏佳熙,等.联合鹿瓜多肽注射液治疗骨性关节炎的疗效分析[J].中国医药,2006,1,10：632-633.
[1]何伟,张俐,王维佳,宫恩年.骨病临床研究,北京[M].北京科学技术出版社.2006,1(1)：133-144.
[2]何斌,史晨辉.尿激酶型纤溶酶原激活物系统与软骨降解[J].农垦医学2005,6,27(3)：229-231.
[3]江蓉星,熊华,金桂花.骨性关节炎的临床治疗研究概况[J].中国中医骨伤科杂志2003,2,11(1)：57-59.
[4]曲俊才.膝骨关节炎模型兔关节液中细胞因子白细胞介素1水平及复方归芪液的干预效应[J].中国组织工程研究与临床康复2008,12：20-22.
[5]李西海,梁文娜.软骨下骨骨重塑与骨关节炎的关系[J].国际骨科学杂志2007,1-28(1)：35-37.
[6]刘献祥,等.透骨消痛颗粒防治膝骨性关节炎的机理研究[J].中国中西结合杂志2007,1-27(1)：50-53.
[7]何帮剑,等.玻璃酸钠注射结合中药熏洗治疗膝关节骨性关节炎疗效观察[J].辽宁中医药大学学报2008,10(8)：97-98.
[8]鞠传宝,初海滨,殷泽刚.补肾活血中药治疗膝骨性关节炎的研究进展[J].中医正骨2008,8,20(8)：70-73.
[9]乐宇民,杜建.补肾活血法在治疗骨关节炎中的应用[J].福建中医学院学报2004,2,14(1)：43-45.
[10]王秀华,苏姿兵,田万斌.丹参注射液对兔骨关节炎软骨的影响[J].辽宁中医杂志2003,10,30(10)：860-861
[11]段戡,周江南,成平.丹参加玻璃酸钠关节内注射对家兔实验性膝骨性关节炎软骨退变的影响[J].中医正骨2007,2,19(2)：4-6.
[12]张梅.马钱子对骨关节炎中软骨细胞凋亡与增殖的影响[J].北京中医药大学学报2003,8(5)：35-38.
[13]兰靖杰,戴七一.推拿手法治疗膝关节骨性关节炎研究进展[J].广西中医学院学报2006,9(4)：73-75.
[14]邵华磊,邵尔浩,王继东.手法加中药透敷治疗膝关节骨性关节炎[J].河南中医2005,25,4：49-501.
[15]胡兆平,余有志,岳国平.自助手法配合中药熏洗治疗膝关节骨性关节炎[J].现代中西医结合杂志2006,15(9)：1138.
[16]王珍,李矗.中药复方治疗骨性关节炎的实验研究进展[J].中南药学2007,12,5,(6)：539-541.
[17]牛维,等.补肾活血中药促进体外培养软骨细胞增殖和蛋白质合成的作用[J].中国临床康复2006,10(19)：50-52.
[18]邵敏.补肾活血中药对体外培养软骨细胞SOD, NOS的影响[J].福建中医药2006,37(4)：48-49.
[19]刘坤,刘盛华,宋贵杰.中药防治膝关节炎实验研究概况第11届全国中西医结合骨伤科学术研讨会论文汇编[C]2003：173-174.
[20]陈桂林,王嵩峰.中药内服治疗膝骨性关节炎的实验研究进展[J].甘肃中医2006,19(8)：48-50.
[21]陈崇伟,卫小春.关节软骨胶原变化与骨关节炎的关系[J].中华风湿病学杂志2003,1,7(1)：43-45.
[22]李赛波,吴耀持.膝骨性关节炎组织形态及细胞因子变化与中医药干预的影响[J].中国组织工程与临床康复2008,12(7)：1313-1317.